Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

TCTMD’s Top 10 Most Popular Stories for July 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

July 31, 2025

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

July 24, 2025

Some Ups, Some Downs in Proposed CMS Reimbursement for 2026, Cardiologists Say

News Daily News

Some Ups, Some Downs in Proposed CMS Reimbursement for 2026, Cardiologists Say

July 22, 2025

GLP-1 Drugs May Have Role in Secondary Prevention of AF

News Conference News HRS 2025

GLP-1 Drugs May Have Role in Secondary Prevention of AF

April 28, 2025

April 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

April 2025 Dispatch for the CV Team

April 18, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

CVD Hospitalization in Older Adults Higher in US Than in Denmark

News Daily News

CVD Hospitalization in Older Adults Higher in US Than in Denmark

Michael O'Riordan

February 07, 2025

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.